Literature DB >> 30818060

Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry.

Boback Ziaeian1, Adrian F Hernandez2, Adam D DeVore3, Jingjing Wu4, Haolin Xu4, Paul A Heidenreich5, Roland A Matsouaka6, Deepak L Bhatt7, Clyde W Yancy8, Gregg C Fonarow9.   

Abstract

BACKGROUND: Diabetes mellitus is an increasingly prevalent condition among heart failure (HF) patients. The long-term morbidity and mortality among patients with and without diabetes with HF with reduced (HFrEF), borderline (HFbEF), and preserved ejection fraction (HFpEF) are not well described.
METHODS: Using the Get With The Guidelines (GWTG)-HF Registry linked to Centers for Medicare & Medicaid Services claims data, we evaluated differences between HF patients with and without diabetes. Adjusted Cox proportional-hazard models controlling for patient and hospital characteristics were used to evaluate mortality and readmission outcomes.
RESULTS: A cohort of 86,659 HF patients aged ≥65 years was followed for 3 years from discharge. Unadjusted all-cause mortality was between 4.4% and 5.5% and all-cause hospitalization was between 19.4% and 22.6% for all groups at 30 days. For all-cause mortality at 3 years from hospital discharge, diabetes was associated with an adjusted hazard ratio of 1.27 (95% CI 1.07-1.49, P = .0051) for HFrEF, 0.95 (95% CI 0.55-1.65, P = .8536) for HFbEF, 1.02 (95% CI 0.87-1.19, P = .8551) for HFpEF. For all-cause readmission, diabetes was associated with an adjusted hazard ratio of 1.06 (95% CI 0.87-1.29, P = .5585) for HFrEF, 1.48 (95% CI 1.15-1.90, P = .0023) for HFbEF, and 1.06 (95% CI 0.91-1.22, P = .4747) for HFpEF.
CONCLUSIONS: HFrEF and HFbEF patients with diabetes are at increased risk for mortality and rehospitalization after hospitalization for HF, independent of other patient and hospital characteristics. Among HFpEF patients, diabetes does not appear to be independently associated with significant additional risks.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30818060      PMCID: PMC7664459          DOI: 10.1016/j.ahj.2019.01.006

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  27 in total

1.  Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.

Authors:  Abhinav Sharma; Xin Zhao; Bradley G Hammill; Adrian F Hernandez; Gregg C Fonarow; G Michael Felker; Clyde W Yancy; Paul A Heidenreich; Justin A Ezekowitz; Adam D DeVore
Journal:  Circ Heart Fail       Date:  2018-06       Impact factor: 8.790

Review 2.  Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

Authors:  Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2014-11-24       Impact factor: 24.094

Review 3.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Authors:  Scott D Solomon; Adel R Rizkala; Jianjian Gong; Wenyan Wang; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J Van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Victor C Shi; Martin P Lefkowitz; John J V McMurray
Journal:  JACC Heart Fail       Date:  2017-06-26       Impact factor: 12.035

4.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.

Authors:  Richard K Cheng; Margueritte Cox; Megan L Neely; Paul A Heidenreich; Deepak L Bhatt; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2014-07-22       Impact factor: 4.749

Review 5.  Diabetes Mellitus and Heart Failure.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Am J Cardiol       Date:  2017-05-30       Impact factor: 2.778

6.  Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.

Authors:  Prakash C Deedwania; Mustafa I Ahmed; Margaret A Feller; Inmaculada B Aban; Thomas E Love; Bertram Pitt; Ali Ahmed
Journal:  Eur J Heart Fail       Date:  2011-03-09       Impact factor: 15.534

7.  Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.

Authors:  Linda S Geiss; Jing Wang; Yiling J Cheng; Theodore J Thompson; Lawrence Barker; Yanfeng Li; Ann L Albright; Edward W Gregg
Journal:  JAMA       Date:  2014-09-24       Impact factor: 56.272

8.  Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations.

Authors:  Rey P Vivo; Selim R Krim; Li Liang; Megan Neely; Adrian F Hernandez; Zubin J Eapen; Eric D Peterson; Deepak L Bhatt; Paul A Heidenreich; Clyde W Yancy; Gregg C Fonarow
Journal:  J Am Heart Assoc       Date:  2014-10-16       Impact factor: 5.501

9.  Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

Authors:  Søren L Kristensen; David Preiss; Pardeep S Jhund; Iain Squire; José Silva Cardoso; Bela Merkely; Felipe Martinez; Randall C Starling; Akshay S Desai; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray; Milton Packer
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

10.  The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Pratik B Sandesara; Wesley T O'Neal; Heval M Kelli; Ayman Samman-Tahhan; Muhammad Hammadah; Arshed A Quyyumi; Laurence S Sperling
Journal:  Diabetes Care       Date:  2017-10-19       Impact factor: 19.112

View more
  6 in total

Review 1.  Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Authors:  Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor
Journal:  Circulation       Date:  2019-12-16       Impact factor: 29.690

2.  Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study.

Authors:  B Zareini; Rasmus Rørth; Anders Holt; Ulrik M Mogensen; Christian Selmer; Gunnar Gislason; Morten Schou; Lars Køber; Christian Torp-Pedersen; Morten Lamberts; Søren Lund Kristensen
Journal:  Cardiovasc Diabetol       Date:  2019-06-12       Impact factor: 9.951

Review 3.  The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.

Authors:  Michael V Genuardi; Paul J Mather
Journal:  Ther Adv Cardiovasc Dis       Date:  2021 Jan-Dec

4.  Informal Caregivers' Experiences with Performing Telemonitoring in Heart Failure Care at Home-A Qualitative Study.

Authors:  Ina Thon Aamodt; Irene Lie; Edita Lycholip; Anna Strömberg; Tiny Jaarsma; Jelena Celutkiene; Ragnhild Hellesø
Journal:  Healthcare (Basel)       Date:  2022-07-02

5.  A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.

Authors:  Ziling Mai; Huanqiang Li; Guanzhong Chen; Enzhao Chen; Liwei Liu; Zhubin Lun; Wenguang Lai; Chunyun Zhou; Sijia Yu; Jin Liu; Shiqun Chen; Jiyan Chen; Yong Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-05-24       Impact factor: 3.947

6.  Analysis of National Health and Insurance Registers for All-Cause Mortality in Patients with Heart Failure with and without Diabetes Mellitus in Poland in 2012.

Authors:  Waldemar Wierzba; Adam Wierzba; Andrzej Śliwczyński; Waldemar Karnafel; Jarosław Pinkas; Mariusz Gujski
Journal:  Med Sci Monit       Date:  2019-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.